uniQure NV (QURE) Rating Increased to Buy at Zacks Investment Research
uniQure NV (NASDAQ:QURE) was upgraded by Zacks Investment Research from a “sell” rating to a “buy” rating in a report issued on Thursday. The firm currently has a $8.00 price target on the stock. Zacks Investment Research’s target price suggests a potential upside of 13.64% from the stock’s current price.
According to Zacks, “UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company’s product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands. “
Other equities analysts have also recently issued reports about the stock. Jefferies Group set a $28.00 price objective on shares of uniQure NV and gave the stock a “buy” rating in a research note on Thursday, July 28th. Chardan Capital set a $35.00 price objective on shares of uniQure NV and gave the stock a “buy” rating in a research note on Thursday, July 28th. Cowen and Company reissued a “buy” rating on shares of uniQure NV in a research note on Thursday, July 28th. Piper Jaffray Cos. set a $16.00 price objective on shares of uniQure NV and gave the stock a “buy” rating in a research note on Friday, August 19th. Finally, HC Wainwright started coverage on shares of uniQure NV in a research note on Thursday, August 4th. They issued a “buy” rating and a $21.00 price objective for the company. One investment analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $24.70.
uniQure NV (NASDAQ:QURE) opened at 7.04 on Thursday. uniQure NV has a 1-year low of $6.63 and a 1-year high of $22.79. The company has a 50-day moving average of $7.33 and a 200-day moving average of $8.80. The company’s market capitalization is $176.91 million.
A number of large investors have recently made changes to their positions in QURE. JPMorgan Chase & Co. raised its stake in shares of uniQure NV by 68.5% in the second quarter. JPMorgan Chase & Co. now owns 14,174 shares of the company’s stock worth $104,000 after buying an additional 5,760 shares during the last quarter. Capital Fund Management S.A. bought a new stake in shares of uniQure NV during the third quarter worth $111,000. TFS Capital LLC raised its stake in shares of uniQure NV by 3.0% in the second quarter. TFS Capital LLC now owns 15,156 shares of the company’s stock worth $112,000 after buying an additional 437 shares during the last quarter. Princeton Alpha Management LP bought a new stake in shares of uniQure NV during the second quarter worth $120,000. Finally, Fox Run Management L.L.C. bought a new stake in shares of uniQure NV during the second quarter worth $122,000. Institutional investors own 31.68% of the company’s stock.
About uniQure NV
uniQure N.V. is engaged in the field of gene therapy. The Company is engaged in the discovery, development and commercialization of gene therapies. It has a technology platform that uses as the basis for collaborative product candidates across approximately three therapeutic focus areas, such as Liver/Metabolic Disease, Central Nervous System (CNS) Disease and Cardiovascular Disease.
Receive News & Stock Ratings for uniQure NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure NV and related stocks with our FREE daily email newsletter.